3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Liposarcoma
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Carcinoma in Situ
1
Advanced Malignant Solid Tumors
1
Interventions
Bevacizumab
3
Paclitaxel
2
Lutetium-177
2
Lutetium
2
ribociclib
1
repotrectinib
1
regorafenib
1
pembrolizumab
1
palbociclib
1
olaparib
1
lutetium Lu 177 dotatate
1
copper dotatate CU-64
1
camrelizumab
1
atezolizumab
1
apatinib
1
Tretinoin
1
Radiation
1
Propranolol
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Fulvestrant
1
Drug Therapy
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Digestive System Neoplasms
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT06621277
2024-10-15
JUMP_START
University Hospital Heidelberg
Recruiting
250 enrolled